Tempus AI, Inc. (NASDAQ:TEM) Given Consensus Rating of “Moderate Buy” by Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $61.18.

Several analysts have recently issued reports on TEM shares. William Blair reissued a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Loop Capital dropped their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Wolfe Research lowered shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Finally, TD Cowen restated a “buy” rating and set a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th.

Insider Activity

In other Tempus AI news, CEO Eric P. Lefkofsky sold 562,345 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $50.93, for a total value of $28,640,230.85. Following the completion of the transaction, the chief executive officer now directly owns 9,457,283 shares in the company, valued at approximately $481,659,423.19. This represents a 5.61 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew Polovin sold 1,130 shares of Tempus AI stock in a transaction on Monday, December 16th. The stock was sold at an average price of $40.23, for a total transaction of $45,459.90. Following the transaction, the executive vice president now owns 244,955 shares in the company, valued at approximately $9,854,539.65. This trade represents a 0.46 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,755,906 shares of company stock worth $322,788,693.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in shares of Tempus AI by 13.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock valued at $80,000 after buying an additional 278 shares during the period. First Horizon Advisors Inc. acquired a new stake in Tempus AI during the 3rd quarter valued at approximately $30,000. Geode Capital Management LLC raised its holdings in Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after purchasing an additional 539 shares during the last quarter. Operose Advisors LLC acquired a new position in shares of Tempus AI in the 4th quarter worth approximately $25,000. Finally, Prestige Wealth Management Group LLC boosted its stake in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $47.17 on Friday. The business’s 50 day simple moving average is $55.33 and its 200 day simple moving average is $51.71. Tempus AI has a 1 year low of $22.89 and a 1 year high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.